UY34652A - Anticuerpos humanos frente a toxinas de clostridium difficile - Google Patents
Anticuerpos humanos frente a toxinas de clostridium difficileInfo
- Publication number
- UY34652A UY34652A UY0001034652A UY34652A UY34652A UY 34652 A UY34652 A UY 34652A UY 0001034652 A UY0001034652 A UY 0001034652A UY 34652 A UY34652 A UY 34652A UY 34652 A UY34652 A UY 34652A
- Authority
- UY
- Uruguay
- Prior art keywords
- human antibodies
- antibodies against
- clostridium difficile
- against toxins
- toxins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Se divulgan anticuerpos totalmente humanos que se unen a la toxina A o a la toxina B de Clostridium difficile, o tanto a la toxina A como a la toxina B, composiciones que comprenden los anticuerpos y métodos de uso. Los anticuerpos de la invención son útiles para neutralizar las toxinas de C. difficile, proporcionando así un medio para tratar la enfermedad y síntomas asociados con una infección por C. difficile, así como para diagnosticar una in fección por C. difficile.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261605914P | 2012-03-02 | 2012-03-02 | |
US201261608255P | 2012-03-08 | 2012-03-08 | |
US201261717404P | 2012-10-23 | 2012-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY34652A true UY34652A (es) | 2013-09-02 |
Family
ID=47844536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001034652A UY34652A (es) | 2012-03-02 | 2013-03-01 | Anticuerpos humanos frente a toxinas de clostridium difficile |
Country Status (18)
Country | Link |
---|---|
US (2) | US9399674B2 (es) |
EP (1) | EP2820044A1 (es) |
JP (2) | JP2015509962A (es) |
KR (1) | KR20140130709A (es) |
CN (2) | CN108101983A (es) |
AR (1) | AR090219A1 (es) |
AU (1) | AU2016203511A1 (es) |
BR (1) | BR112014021251A2 (es) |
CA (1) | CA2863536A1 (es) |
HK (1) | HK1200463A1 (es) |
IL (1) | IL233884A0 (es) |
MX (1) | MX2014010527A (es) |
NZ (2) | NZ628943A (es) |
RU (2) | RU2017127772A (es) |
SG (2) | SG11201405087PA (es) |
TW (1) | TWI592422B (es) |
UY (1) | UY34652A (es) |
WO (1) | WO2013130981A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2564695T3 (en) | 2009-07-08 | 2015-05-26 | Kymab Ltd | Animal models and therapeutic molecules |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
CN107056936B (zh) | 2011-09-19 | 2021-09-03 | 科马布有限公司 | 免疫球蛋白基因多样性的操纵及多抗体治疗剂 |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US9181632B1 (en) | 2013-09-09 | 2015-11-10 | Merck Sharp & Dohme Corp. | C.difficile toxin B CROP domain peptides, antibodies and complexes thereof |
EP3051942B1 (en) | 2013-10-01 | 2020-09-02 | Kymab Limited | Animal models and therapeutic molecules |
CA2976976C (en) | 2015-02-19 | 2023-02-28 | Immune Biosolutions Inc. | Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof |
JP2018517670A (ja) * | 2015-04-15 | 2018-07-05 | メディミューン,エルエルシー | クロストリジウム・ディフィシル(Clostridium difficile)感染および関連疾患の治療方法 |
EA201892362A1 (ru) | 2016-04-18 | 2019-04-30 | Селлдекс Терапьютикс, Инк. | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения |
US11299751B2 (en) * | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
US20210032351A1 (en) * | 2017-12-13 | 2021-02-04 | Xdcexplorer (Shanghai) Co., Ltd. | Egfrviii antibody and conjugate, and preparation method and use thereof |
US20220080036A1 (en) * | 2018-09-18 | 2022-03-17 | Vanderbilt University | Human monoclonal antibodies to staphylococcal aureus isd proteins and uses thereof |
US20200148762A1 (en) * | 2018-11-09 | 2020-05-14 | Avamab Pharma Inc. | Methods for regulating endogenous production of antibodies against infectious diseases |
CN111793130B (zh) * | 2019-03-20 | 2021-09-14 | 华中农业大学 | 一株副猪嗜血杆菌CdtB杂交瘤细胞及单克隆抗体应用 |
KR102376876B1 (ko) | 2020-04-09 | 2022-03-21 | 대진대학교 산학협력단 | 무독성의 클로스트리디움 디피실 독소단백질-단편 및 이의 용도 |
WO2021219786A1 (en) | 2020-04-30 | 2021-11-04 | Gottfried Himmler | Anti-toxin secretory iga2 preparation |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4879218A (en) | 1982-09-13 | 1989-11-07 | Virginia Tech Intellectual Properties, Inc. | Antibody for C.difficile |
US5358868A (en) | 1987-11-24 | 1994-10-25 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
GB8727489D0 (en) | 1987-11-24 | 1987-12-23 | Connaught Lab | Detoxification of pertussis toxin |
US5221618A (en) | 1987-11-24 | 1993-06-22 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
US5244657A (en) | 1987-11-24 | 1993-09-14 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
US5332583A (en) | 1987-11-24 | 1994-07-26 | Connaught Laboratories Limited | Vaccine containing genetically-detoxified pertussis holotoxin |
US5224657A (en) | 1989-05-23 | 1993-07-06 | Kabushiki Kaisha Toshiba | Cryogenic refrigerator |
US5231003A (en) * | 1990-05-11 | 1993-07-27 | Cambridge Bioscience Corporation | Monoclonal antibodies specific for toxin b of clostridium difficile |
CA2761116A1 (en) * | 1995-04-27 | 1996-10-31 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
DE19739685A1 (de) | 1997-09-10 | 1999-03-11 | Eichel Streiber Christoph Von | Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile |
EP1568378B1 (en) | 1997-10-20 | 2016-03-16 | Sanofi Pasteur Biologics, LLC | Immunization against Clostridium difficile disease |
US6969520B2 (en) | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
WO1999020304A1 (en) | 1997-10-20 | 1999-04-29 | Oravax, Inc. | Passive immunization against clostridium difficile disease |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
GB0309126D0 (en) | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
CN1809591A (zh) * | 2003-05-21 | 2006-07-26 | 米德列斯公司 | 针对炭疽芽孢杆菌保护性抗原的人单克隆抗体 |
PT2857418T (pt) | 2004-02-06 | 2017-10-20 | Univ Massachusetts | Anticorpos contra toxinas de clostridium difficile e utilizações dos mesmos |
WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
US20090087478A1 (en) * | 2004-12-27 | 2009-04-02 | Progenics Pharmaceuticals (Nevada), Inc. | Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them |
JP5551933B2 (ja) * | 2006-04-17 | 2014-07-16 | シェーリング−プラウ・リミテッド | 組み換え弱毒化Clostridium生物体およびワクチン |
ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
RU2465893C2 (ru) * | 2006-08-02 | 2012-11-10 | Йоханнес Гутенберг-Университет Майнц | Лекарственное средство от отравлений |
US8084684B2 (en) | 2006-10-09 | 2011-12-27 | Solexel, Inc. | Three-dimensional thin-film solar cells |
US20110020356A1 (en) | 2007-12-07 | 2011-01-27 | Lin Fang | Therapeutic clostridium difficile antibody compositions |
BRPI0906060A2 (pt) | 2008-02-28 | 2015-12-01 | 3M Innovative Properties Co | anticorpos isolados, métodos de preparo de um anticorpo anti-clostridium difficile, composição e método para a detecção da presença de um esporo de clostridium difficile em uma amostra |
US8709428B2 (en) | 2009-02-20 | 2014-04-29 | Health Protection Agency | Antibodies to Clostridium difficile toxins |
CN102471378B (zh) | 2009-06-26 | 2014-04-02 | 瑞泽恩制药公司 | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 |
AU2010299552A1 (en) * | 2009-09-23 | 2012-04-05 | Thomas Julius Borody | Therapy for enteric infections |
US20120282274A1 (en) | 2009-11-20 | 2012-11-08 | Northshore University Health System Research Institute | Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment |
WO2011097603A1 (en) | 2010-02-08 | 2011-08-11 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
ES2757675T3 (es) * | 2010-04-15 | 2020-04-29 | Progenics Pharm Inc | Anticuerpos para el tratamiento de la infección y enfermedad asociada a Clostridium difficile |
-
2013
- 2013-03-01 BR BR112014021251A patent/BR112014021251A2/pt not_active IP Right Cessation
- 2013-03-01 SG SG11201405087PA patent/SG11201405087PA/en unknown
- 2013-03-01 CN CN201711446090.7A patent/CN108101983A/zh active Pending
- 2013-03-01 UY UY0001034652A patent/UY34652A/es unknown
- 2013-03-01 CA CA2863536A patent/CA2863536A1/en not_active Abandoned
- 2013-03-01 JP JP2014560093A patent/JP2015509962A/ja active Pending
- 2013-03-01 AR ARP130100670A patent/AR090219A1/es unknown
- 2013-03-01 RU RU2017127772A patent/RU2017127772A/ru not_active Application Discontinuation
- 2013-03-01 EP EP13708641.9A patent/EP2820044A1/en not_active Withdrawn
- 2013-03-01 US US13/782,444 patent/US9399674B2/en active Active
- 2013-03-01 NZ NZ628943A patent/NZ628943A/en not_active IP Right Cessation
- 2013-03-01 TW TW102107190A patent/TWI592422B/zh not_active IP Right Cessation
- 2013-03-01 SG SG10201610123UA patent/SG10201610123UA/en unknown
- 2013-03-01 NZ NZ714516A patent/NZ714516A/en not_active IP Right Cessation
- 2013-03-01 KR KR1020147026227A patent/KR20140130709A/ko not_active Application Discontinuation
- 2013-03-01 RU RU2014139552A patent/RU2628305C2/ru not_active IP Right Cessation
- 2013-03-01 CN CN201380012035.0A patent/CN104203976A/zh active Pending
- 2013-03-01 MX MX2014010527A patent/MX2014010527A/es unknown
- 2013-03-01 WO PCT/US2013/028630 patent/WO2013130981A1/en active Application Filing
-
2014
- 2014-07-30 IL IL233884A patent/IL233884A0/en unknown
-
2015
- 2015-01-09 HK HK15100241.0A patent/HK1200463A1/xx unknown
-
2016
- 2016-05-27 AU AU2016203511A patent/AU2016203511A1/en not_active Abandoned
- 2016-06-01 US US15/170,602 patent/US20160264650A1/en not_active Abandoned
-
2017
- 2017-12-01 JP JP2017231934A patent/JP2018029625A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112014021251A2 (pt) | 2017-06-27 |
AU2013203942A8 (en) | 2016-08-11 |
JP2018029625A (ja) | 2018-03-01 |
NZ714516A (en) | 2017-06-30 |
KR20140130709A (ko) | 2014-11-11 |
RU2628305C2 (ru) | 2017-08-15 |
HK1200463A1 (en) | 2015-08-07 |
AU2016203511A1 (en) | 2016-06-16 |
EP2820044A1 (en) | 2015-01-07 |
AR090219A1 (es) | 2014-10-29 |
NZ628943A (en) | 2016-08-26 |
AU2013203942B2 (en) | 2016-03-10 |
IL233884A0 (en) | 2014-09-30 |
MX2014010527A (es) | 2014-10-14 |
RU2017127772A (ru) | 2019-02-04 |
CN104203976A (zh) | 2014-12-10 |
TWI592422B (zh) | 2017-07-21 |
RU2014139552A (ru) | 2016-04-20 |
JP2015509962A (ja) | 2015-04-02 |
SG11201405087PA (en) | 2014-09-26 |
CA2863536A1 (en) | 2013-09-06 |
WO2013130981A1 (en) | 2013-09-06 |
CN108101983A (zh) | 2018-06-01 |
SG10201610123UA (en) | 2017-01-27 |
US20130230531A1 (en) | 2013-09-05 |
US9399674B2 (en) | 2016-07-26 |
AU2013203942A1 (en) | 2013-09-19 |
US20160264650A1 (en) | 2016-09-15 |
TW201350501A (zh) | 2013-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY34652A (es) | Anticuerpos humanos frente a toxinas de clostridium difficile | |
UY34206A (es) | Anticuerpo monoclonal de interleucina-31 | |
CO7151521A2 (es) | Anticuerpos anti-fcrn | |
MY167585A (en) | Disposable diaper | |
HK1201296A1 (en) | Modified fc region of antibody fc | |
CR20150329A (es) | Inmunoglobulinas heterodiméricas | |
PH12014501427A1 (en) | Anti-php-tau antibodies and their uses | |
TWD159089S (zh) | 錶 | |
UY34836A (es) | Nuevo organismos | |
TWD165137S (zh) | 錶 | |
UY34456A (es) | Anticuerpos anti-il-36r | |
MY165759A (en) | Pull-on diaper | |
BR112013028512A2 (pt) | cápsula | |
TWD162033S (zh) | 手錶 | |
BR112014004162A2 (pt) | anticorpos contra clostridium difficile | |
TWD159086S (zh) | 錶 | |
UY34644A (es) | Polipéptidos de unión a cx3cr1 | |
TWD159085S (zh) | 錶 | |
TWD159090S (zh) | 錶 | |
TWD158666S (zh) | 錶 | |
MY166103A (en) | Disposable diaper | |
MY167652A (en) | Disposable diaper | |
BR112014026634A2 (pt) | direcionador | |
IL239063A0 (en) | Antibodies against clostridium difficile | |
BR112014027219A2 (pt) | método |